companies with FDA approved anti-obesity drugs on the market. Other players looking to enter the space are Novo Nordisk (NYSE: NVO ) and Zafgen (NASDAQ: ZFGN ). All will have a presence at Obesity Complete Story »
COPENHAGEN, Oct 15 (Reuters) - NNIT, the information technology unit of Danish pharmaceutical company Novo Nordisk , is expected to announce plans for an initial public offering (IPO) on the Nasdaq Copenhagen exchange next week, daily Berlingske reported on Wednesday.
Pg. 25) " and the ever-present global effort to improve healthcare standards. The Diabetes Market Also from the Novo - Nordisk 2013 annual report: 382 million people with diabetes worldwide Only 45-50 million insulin users $40 billion Diabetes
blood sugar levels. The GLP-1 market is dominated by Novo Nordisk 's Victoza, which generated sales of $2.07 billion ..... billion. Trulicity has been found as non-inferior to Novo Nordisk 's standard GLP-1 therapy, Victoza, in head-to
The European Commission approves Novo Nordisk 's (NYSE: NVO ) Xultophy for the treatment of adult patients with ..... degludec ( Tresiba ) and liraglutide ( Victoza ). Novo plans to launch the product in Europe in 1H 2015
In a Phase 3b clinical trial , Novo Nordisk 's (NYSE: NVO ) Ryzodeg (insulin degludec/insulin aspart) administered twice daily provided successful glycemic control with fewer injections
COPENHAGEN, Sept 18 (Reuters) - Novo Nordisk 's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.
COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk 's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according...
By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different
* Novo 's Saxenda safe, effective enough for approval - FDA panel